Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adaptive BiotechnologiesADPT +1.90%67 Return-on-Tangible-Asset is -20.61% as of Mar. 2026. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Adaptive Biotechnologies ranks worse than 65.26% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Adaptive Biotechnologies's annualizedNet Income for the quarter that ended in Mar. 2026 was $-80.1 Mil. Adaptive Biotechnologies's average total tangible assets for the quarter that ended in Mar. 2026 was $388.9 Mil. Therefore, Adaptive Biotechnologies's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -20.61%.
The historical rank and industry rank for Adaptive Biotechnologies's Return-on-Tangible-Asset or its related term are showing as below:
ADPT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -35.53 Med: -21.69 Max: -13
Current: -13
During the past 9 years, Adaptive Biotechnologies's highest Return-on-Tangible-Asset was -13.00%. The lowest was -35.53%. And the median was -21.69%.
ADPT's Return-on-Tangible-Asset is ranked worse than 65.26% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs ADPT: -13.00
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Adaptive Biotechnologies Return-on-Tangible-Asset Related Terms
Adaptive Biotechnologies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Adaptive Biotechnologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADPT vs GRAL, WGS, RDNT: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -20.61% mean?
Adaptive Biotechnologies (ADPT) has a Return-on-Tangible-Asset of -20.61% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #139 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 65.3%.
Is Adaptive Biotechnologies' Return-on-Tangible-Asset too high?
Adaptive Biotechnologies' current Return-on-Tangible-Asset is -20.61%. Based on the distribution chart, Adaptive Biotechnologies ranks #139 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Return-on-Tangible-Asset compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #139 out of 213 companies for Return-on-Tangible-Asset. This places Adaptive Biotechnologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Return-on-Tangible-Asset is -20.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.05, compared to a current price of $21.45 — trading 113.4% above its estimated fair value. The current Return-on-Tangible-Asset is -20.61%. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Return-on-Tangible-Asset is -20.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of $21.45 is trading 113.4% above its estimated GF Value™ of $10.05.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for ADPT:
Return-on-Tangible-Asset: -20.61%
GF Value™: $10.05 vs. price of $21.45 (113.4% above fair value)
No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
67GF Score
Get the complete analysis for ADPT
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADPT has been successfully added to your 
